Samir Khan

Bill C-15 with respect to proposal to change the tax treatment on income earned by Canadian insurance companies on foreign property. Changes programs and policies to increase private sector infrastructure investment and attract foreign capital to Canada Standards for banking (open banking) and regulation of data processing including the use of artificial intelligence. Policies and programs related to Canada trade relations with other countries and Canada's economic competitiveness. Improve the Global Minimum Tax Act to promote international coordination and harmonization on timing and operation. Office of the Superintendent of Financial Institutions and the Supervision of Insurers and Banks in particular to improve the ability of Canadian companies to compete and grow outside of Canada. Insurance Companies Act and regulations to amend the Act to permit greater investment by insurers outside of the financial sector and to improve the ability of Canadian companies to compete and grow outside of Canada. Healthcare policy, specifically in relating to, employee benefits programs, including long-term disability, drug benefit plans and health data standards. Veterans Benefits including programs and policies that provide financial and other assistance to current and former members of the Canadian Armed Forces. Privacy, Human Rights and Insurance including the Privacy Act, Human Rights Act and the Canada Labour Code.

Supporting legislative changes to allow the electronic delivery of governance documents in the financial sector as proposed in the 2024 federal budget. Veterans Benefits including programs and policies that provide financial and other assistance to current and former members of the Canadian Armed Forces. The Pension Benefits Act and the Tax Act including annuities. The Income Tax Act and Budget 2023 proposal to change the tax treatment on Canadian dividends received by Canadian insurance companies. Standards for banking and health data (open banking, health information). Privacy, Human Rights and Insurance including the Privacy Act, Human Rights Act and the Canada Labour Code. Policies and programs related to Canada trade relations with other countries. Office of the Superintendent of Financial Institutions Guidelines on Insurance and Banking. Insurance Companies Act and regulations. Healthcare policy, specifically in relating to, employee benefits programs, including long-term disability and drug benefit plans. Global Minimum Tax Act to promote international coordination and harmonization on the timing and operation. Ensuring the passage of Bill C-27 - the Consumer Privacy Protection Act as drafted by the government. Canada’s system and programs for detecting and deterring money laundering. Access to Hong Kong Pensions for permanent residents of Canada

Public health and prevention programs including the Public Health Agency of Canada and efforts to support the development and procurement of innovative vaccines and therapies to address major public health issues such as pandemic preparedness and RSV Federally-funded public drug plans, including the Non-Insured Health Benefits program, Canadian Armed Forces Drug Benefit List and veteran programs, with respect to reimbursement for drug products for beneficiaries Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada Annual federal Budgets and Budget updates relating to the biopharmaceutical industry. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.

Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments. The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection. Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada. Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally. Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic. Public policy issues related to Health Canada's review of NCE Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry. Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada. Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices. National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians. Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process. Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage. Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Raise awareness of challenges that cancer clinicians face on behalf of their patients in receiving equitable access to cancer care, specifically: - expanding access to diagnostics, including molecular genetics testing - ensuring faster, more equitable access to new cancer therapies - improving efficiencies in patient care, and addressing human resource contraints

Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Engagement with officials regarding Health Canada’s National Rare Disease Drug Strategy, and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a priority of the government

Issues related to U.S. pharmaceutical importation, trade and policies, including research and development, regulatory authorizations, funding of medicines, supply sources and supply chains. Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy. Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board Federally-funded Public Drug Plans, with respect to reimbursement for medicines for federal plan beneficiaries. Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Enhancements related to intellectual property legislation, regulations and policies applicable to pharmaceuticals. Implementation of the National Strategy for Drugs for Rare Diseases and the Pharmacare Act.

Species at Risk Act: With respect to possible legislative and regulatory changes to SARA Small Modular Reactors: Advocate for government support for the development of SMRs to support government energy and climate change policies Science and Technology: Advocate for continued support for nuclear research and development, including our production and development of life-saving medical isotopes with industry and Indigenous partners. Nuclear Waste Management: Advocate policies with respect to long-term nuclear waste storage. Nuclear Liability Act: Lobby government with respect to upcoming changes to the regulations around the NLA Nuclear Energy: Advocate for greater recognition of nuclear energy and its role in fighting climate change and supporting CANDU technology development and innovation. International Trade: Advocate for policies or programs that assist the Canadian nuclear industry in developing/increasing foreign trade. Fisheries Act: With respect to possible changes to the Fisheries Act involving destruction of fish and/or fish habitat including Bill C68 and ensuing regulations Department of Finance: With respect to possible changes to regulations around private corporate pension plans and various proposed tax measures Climate: Inclusion of nuclear energy in the program as a means of maximizing emissions-free nuclear power generation to assist Canada is achieving its emissions reduction objectives. Canadian Nuclear Safety Control Act: Regulatory documents pertaining to the design,construction and operation of new nuclear power plants and continued safe operation of existing plants. Canadian Nuclear Labs - Outline areas of possible co-operation with respect to the future activities of CNL including, medical isotopes, R&D, refurbishment of operating reactors and development of new reactors. Canadian Environmental Assessment Act and the Impact Assessment Act. Bruce Power will be lobbying the government with respect to the Impact Assessment Act and the regulation. Bruce Power is interested in discussing policies and programs that support the increased use of electrical vehicles

Contribute insights to optimize the regulatory approval for generic drugs in order to increase the efficiency of drug approvals.

Raise awareness of the company HIPRA and its plans to expand in Canada to support routine and pandemic vaccination programs.

Related to the life sciences, research and the digital ecosystems, we need to make sure that Canada creates an environment that is globally competitive Related to legislations on data privacy we need to make sure that Canada has legislations that are harmonized across provinces and federal governments as well as global standards. Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.

Policies regarding the availability of Novavax's COVID-19 vaccine throughout Canada. Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the Biomanufacturing and Life Sciences Strategy with a focus on the importance of vaccines for public health in Canada. Canada’s Strategic Innovation Fund, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a focus of the government’s post-COVID recovery plan.

Support for new research and campus infrastructure. Increased funding and program design for various programs administered by Social Sciences and Humanities Research Council (SSHRC), Natural Sciences and Engineering Research Council (NSERC), and Canadian Institutes of Health Research (CIHR). Funding or support with respect to international development cooperation (student and academic mobility, internships, research collaboration, exchanges, technical assistance). Discussions regarding possible research and development initiatives for, and investments in, partnerships with the University of Calgary. Discussions concerning potential research and development initiatives and investments related to clean energy, environmental research and climate change policy. Discussions about policy implementation regarding the academic visa process in support of international faculty recruitment with respect to changes to the Immigration and Refugee Protection Regulations. Budget bills in support of federal funding for post-secondary education, research, innovation, science and technology.